Literature DB >> 21733739

Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease.

Radu Constantinescu, Megan Romer, Henrik Zetterberg, Lars Rosengren, Karl Kieburtz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21733739     DOI： 10.1016/j.parkreldis.2011.06.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  10 in total

1.  Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.

Authors:  Nicholas S Caron; Raul Banos; Christopher Yanick; Amirah E Aly; Lauren M Byrne; Ethan D Smith; Yuanyun Xie; Stephen E P Smith; Nalini Potluri; Hailey Findlay Black; Lorenzo Casal; Seunghyun Ko; Daphne Cheung; Hyeongju Kim; Ihn Sik Seong; Edward J Wild; Ji-Joon Song; Michael R Hayden; Amber L Southwell
Journal:  J Neurosci       Date:  2020-12-11       Impact factor: 6.167

2.  Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease.

Authors:  Elyse Rosa; Sujeivan Mahendram; Yazi D Ke; Lars M Ittner; Stephen D Ginsberg; Margaret Fahnestock
Journal:  Neurobiol Aging       Date:  2016-08-31       Impact factor: 4.673

3.  Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.

Authors:  Tua Vinther-Jensen; Lars Börnsen; Esben Budtz-Jørgensen; Cecilie Ammitzbøll; Ida U Larsen; Lena E Hjermind; Finn Sellebjerg; Jørgen E Nielsen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-28

4.  Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?

Authors:  Valter Niemelä; Anne-Marie Landtblom; Kaj Blennow; Jimmy Sundblom
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

5.  Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.

Authors:  Rachael I Scahill; Paul Zeun; Katherine Osborne-Crowley; Eileanoir B Johnson; Sarah Gregory; Christopher Parker; Jessica Lowe; Akshay Nair; Claire O'Callaghan; Christelle Langley; Marina Papoutsi; Peter McColgan; Carlos Estevez-Fraga; Kate Fayer; Henny Wellington; Filipe B Rodrigues; Lauren M Byrne; Amanda Heselgrave; Harpreet Hyare; Cristina Sampaio; Henrik Zetterberg; Hui Zhang; Edward J Wild; Geraint Rees; Trevor W Robbins; Barbara J Sahakian; Douglas Langbehn; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2020-05-26       Impact factor: 44.182

Review 6.  Targeting Tau to Treat Clinical Features of Huntington's Disease.

Authors:  Maria Masnata; Shireen Salem; Aurelie de Rus Jacquet; Mehwish Anwer; Francesca Cicchetti
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

Review 7.  The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Authors:  Jennifer M Deger; Julia E Gerson; Rakez Kayed
Journal:  Aging Cell       Date:  2015-06-05       Impact factor: 9.304

8.  Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.

Authors:  Filipe Brogueira Rodrigues; Lauren Byrne; Peter McColgan; Nicola Robertson; Sarah J Tabrizi; Blair R Leavitt; Henrik Zetterberg; Edward J Wild
Journal:  J Neurochem       Date:  2016-09-20       Impact factor: 5.372

9.  Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.

Authors:  Valter Niemelä; Joachim Burman; Kaj Blennow; Henrik Zetterberg; Anders Larsson; Jimmy Sundblom
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

Review 10.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.